Our client, a multinational mid-sized pharma company needed assistance in running a clinical trial to evaluate the safety and efficacy of an adjunctive therapy in the acute treatment of moderate to severe COVID-19 patients.
Read our latest case study and learn how we are driving operational approaches to evaluate the safety and efficacy of their therapies in moderate to severe COVID-19 patients. From being awarded the studies to date we have:
- Quickly activated sites within 20 days
- Achieved FPI within 30 days of study award
- Recruited Patients ahead of time
- Comprehensive trial oversight through our in-house analytics platform
Please complete the form to download our case study.